Login Register
English
0

Cart

$ 0
OR
Catalog no Product name Protocol name IF Magazine title
ABT2025 HRP Conjugated Anti-GFP Tag Mouse Monoclonal Antibody (3D3) Drosophila AK-3, a homolog of human CKMT1B, is essential for spermiogenesis.(ABT2025-3.7) 3.7  Reproduction 
ABT2060 Anti-Myc Tag Mouse Monoclonal Antibody (2D5) Drosophila AK-3, a homolog of human CKMT1B, is essential for spermiogenesis.(ABT2060-3.7) 3.7 Reproduction
KTB1100 CheKine™ Micro Lactate Assay Kit dsHMGB1, released from IL-17A-induced pyroptotic prostate epithelial cells, drives M1 polarization by promoting Pfkp-mediated glycolysis via Jak2/Stat1 …(KTB1100-10) 10
KTA4002 Mitochondrial Permeability Transition Pore Assay DST-3, a novel cryptotanshinone derivate, attenuates glutamate excitotoxicity after ischemic stroke via CREB-Homer1 axis activation(KTA4002-8) 8 International Immunopharmacology
KTA4001 Mitochondrial Membrane Potential Assay Kit (JC-1) DST-3, a novel cryptotanshinone derivate, attenuates glutamate excitotoxicity after ischemic stroke via CREB-Homer1 axis activation(KTA4001-8) 8 Phytomedicine
KTB1100 CheKine™ Micro Lactate Assay Kit Dual activation of GCGR/GLP1R signaling ameliorates intestinal fibrosis via metabolic regulation of histone H3K9 lactylation in epithelial cells(KTB1100-14.7) 14.7 Aquaculture Reports
A21010 HRP, Goat Anti-Mouse IgG Dual Effects: Intrastriatal Injection of α-syn N103/tau N368 Preformed Fibrils Promotes Endogenous α-synuclein Aggregates in the Proximal Colon(A21010-) Cellular and Molecular Neurobiology
KTD3001 Protein Quantification Kit (BCA Assay) Dual inhibitory potential of ganoderic acid A on GLUT1/3: computational and in vitro insights into targeting glucose metabolism in human lung cancer.(KTD3001-4) 4 RSC advances
KTD104 Dual Lactylation Mechanism Orchestrates Ferroptosis Resistance in PRCC-TFE3 rRCC: H3K18la-Mediated FTL Transcription and p300-Driven FTL Lactylation(KTD104-) Oncology Letters
PRP100503 Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy(PRP100503-3) 3 Journal of Controlled Release